Who Buys Dacarbazine from India — 384 Importers Behind a $1.4M Market

The 384 buyers of Dacarbazine from India can be categorized into several segments:

1. Distributors: Entities that purchase Dacarbazine in bulk to supply to various healthcare providers. For instance, S T C Salehiya Trading and Salehiya Trading Company in Saudi Arabia function as distributors, facilitating the distribution of Dacarbazine within the region.

2. Hospital Groups: Large healthcare institutions procuring Dacarbazine directly for patient treatment. Multicare Pharmaceuticals Philippines likely represents a hospital group or is closely affiliated with one, ensuring a steady supply for oncology departments.

3. Government Procurement Agencies: National bodies responsible for acquiring medicines for public healthcare facilities. Kimadia in Iraq serves as the state company for importing pharmaceuticals, including Dacarbazine, to meet public health needs.

4. Re-exporters: Companies that import Dacarbazine with the intent to export it to other markets. While specific re-exporters are not identified among the top buyers, this segment plays a role in global distribution chains.

5. Contract Manufacturers: Firms that import Dacarbazine as an active pharmaceutical ingredient (API) for formulation into finished products. CPC "Biocon" LLC in Poland may engage in such activities, leveraging imported APIs for local manufacturing.

Each segment exhibits distinct purchasing behaviors. Distributors and hospital groups often place large, periodic orders to maintain inventory levels, while government agencies may procure through structured tender processes, leading to bulk purchases at scheduled intervals. Re-exporters' orders are influenced by demand fluctuations in target markets, and contract manufacturers align their procurement with production schedules and regulatory approvals.

Understanding the import regulations for Dacarbazine in the top importing countries is crucial:

The demand for Dacarbazine in importing countries is driven by several factors:

1. Disease Prevalence: Dacarbazine is primarily used in the treatment of certain cancers, including Hodgkin's lymphoma and malignant melanoma. The prevalence of these cancers in countries like Saudi Arabia and the Philippines contributes to the consistent demand for this chemotherapeutic agent.

2. Government Healthcare Programs: Many importing countries have established healthcare programs aimed at providing essential medicines to their populations. For example, national health services in countries like Sri Lanka and Morocco include cancer treatment in their public health offerings, necessitating the procurement of drugs like Dacarbazine.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in countries such as Venezuela have led to increased access to cancer treatments, thereby boosting the demand for essential oncology drugs.

4. WHO Essential Medicines List Procurement: Dacarbazine's inclusion in the WHO Model List of Essential Medicines underscores its importance in cancer treatment protocols, prompting countries to prioritize its procurement to meet international healthcare standards.

5. Tender-Based Purchasing: Government and large healthcare institutions often procure medicines through tender systems to ensure cost-effectiveness and supply chain efficiency. This approach is prevalent in countries like Saudi Arabia and the Philippines, where bulk purchasing through tenders ensures a steady supply of Dacarbazine to meet patient needs.

The presence of 384 buyers across 110 countries indicates a broad and sustained global demand for Dacarbazine, reflecting its critical role in oncology treatment regimens worldwide.

The 384 buyers of Dacarbazine from India can be categorized into several segments:

1. Distributors: Entities that purchase Dacarbazine in bulk to supply to various healthcare providers. For instance, S T C Salehiya Trading and Salehiya Trading Company in Saudi Arabia function as distributors, facilitating the distribution of Dacarbazine within the region.

2. Hospital Groups: Large healthcare institutions procuring Dacarbazine directly for patient treatment. Multicare Pharmaceuticals Philippines likely represents a hospital group or is closely affiliated with one, ensuring a steady supply for oncology departments.

3. Government Procurement Agencies: National bodies responsible for acquiring medicines for public healthcare facilities. Kimadia in Iraq serves as the state company for importing pharmaceuticals, including Dacarbazine, to meet public health needs.

4. Re-exporters: Companies that import Dacarbazine with the intent to export it to other markets. While specific re-exporters are not identified among the top buyers, this segment plays a role in global distribution chains.

5. Contract Manufacturers: Firms that import Dacarbazine as an active pharmaceutical ingredient (API) for formulation into finished products. CPC "Biocon" LLC in Poland may engage in such activities, leveraging imported APIs for local manufacturing.

Each segment exhibits distinct purchasing behaviors. Distributors and hospital groups often place large, periodic orders to maintain inventory levels, while government agencies may procure through structured tender processes, leading to bulk purchases at scheduled intervals. Re-exporters' orders are influenced by demand fluctuations in target markets, and contract manufacturers align their procurement with production schedules and regulatory approvals.

Understanding the import regulations for Dacarbazine in the top importing countries is crucial:

The demand for Dacarbazine in importing countries is driven by several factors:

1. Disease Prevalence: Dacarbazine is primarily used in the treatment of certain cancers, including Hodgkin's lymphoma and malignant melanoma. The prevalence of these cancers in countries like Saudi Arabia and the Philippines contributes to the consistent demand for this chemotherapeutic agent.

2. Government Healthcare Programs: Many importing countries have established healthcare programs aimed at providing essential medicines to their populations. For example, national health services in countries like Sri Lanka and Morocco include cancer treatment in their public health offerings, necessitating the procurement of drugs like Dacarbazine.

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage in countries such as Venezuela have led to increased access to cancer treatments, thereby boosting the demand for essential oncology drugs.

4. WHO Essential Medicines List Procurement: Dacarbazine's inclusion in the WHO Model List of Essential Medicines underscores its importance in cancer treatment protocols, prompting countries to prioritize its procurement to meet international healthcare standards.

5. Tender-Based Purchasing: Government and large healthcare institutions often procure medicines through tender systems to ensure cost-effectiveness and supply chain efficiency. This approach is prevalent in countries like Saudi Arabia and the Philippines, where bulk purchasing through tenders ensures a steady supply of Dacarbazine to meet patient needs.

The presence of 384 buyers across 110 countries indicates a broad and sustained global demand for Dacarbazine, reflecting its critical role in oncology treatment regimens worldwide.